Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin

Trial Profile

Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Atorvastatin (Primary) ; Seladelpar (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 01 Feb 2012 Results assessing the effect of treatment lipoprotein particle subfractions published in Atherosclerosis.
    • 14 Jun 2009 Results presented at the 15th International Symposium on Atherosclerosis.
    • 18 Nov 2008 Results have been presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension according to a Metabolex media release; results have also been reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top